DGAP-News

​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021

DGAP-News: PAION AG / Key word(s): Quarterly / Interim Statement ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021 12.05.2021 / 07:30 The issuer is solely responsible for the content of this announcement. PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2021

- Remimazolam launches in the U.S. and South Korea in the first quarter of 2021

- EU market approval received for remimazolam in procedural sedation in March 2021

- Good progress in commercialization of remimazolam in the U.S., Japan, China and South Korea through our partners

- Expansion of European product portfolio with GIAPREZA^(R) and XERAVA^(R); PAION further drives specialty pharma transformation

- Successful rights issue of EUR 7.8 million completed in April 2021

- Revenues of EUR 3.2 million

- Cash and cash equivalents of EUR 13.9 million as of 31 March 2021

Aachen (Germany), 12 May 2021 - The specialty pharmaceutical company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard) today reports its consolidated financial results according to International Financial Reporting Standards (IFRS) for the first quarter of 2021.

Dr. Jim Phillips, CEO of PAION AG, commented: "The first quarter of 2021 brought important progress in our transformation into a specialty pharma company. Our in-house developed remimazolam was approved in procedural sedation in the EU and successfully launched in other countries around the globe through partners. Another key to our future success has been the addition of GIAPREZA^(R) and XERAVA^(R) to our product portfolio in January, which allows the creation of a more efficient sales and marketing organization. We are now building our commercial organization and preparing launches for all three products in the second half of 2021, addressing important unmet medical needs."